Perlegen and 454 to Collaborate in Drug Response Sequencing Study
News Oct 04, 2007
Perlegen Sciences, Inc., and 454 Life Sciences, part of Roche Diagnostics, announced a collaboration to conduct large scale genetic re-sequencing in hundreds of human DNA samples collected by Perlegen from individuals with specific responses to a widely prescribed class of drug.
The goal of the collaboration will be to determine whether sufficient genetic variation can be identified and validated to create a clinical test that will predict how individuals might respond to this class of medicines.
Pursuant to the terms of the agreement, Perlegen and 454 will each re-sequence select portions of the genome within each sample, using 454 Sequencing™ technology and DNA amplified with Perlegen’s proprietary sample preparation and amplification technologies. The parties’ data analysis teams will jointly study the combined results to determine how significant a role variations in genetic sequence plays in patient response to this drug class.
“We are pleased to be working with 454 in this landmark pharmacogenomic study that combines 454’s exceptional next generation sequencing technology with Perlegen’s expertise in defining genetic variation on a carefully selected sample set,” commented Bryan Walser, MD, Chief Executive Officer of Perlegen Sciences. “This study holds the promise to improve therapeutic outcomes for a vast number of patients.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE